Insider Transactions in Q4 2024 at Silverback Therapeutics, Inc. (SBTX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 17
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
27,272
-16.66%
|
$327,264
$12.06 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,272
+14.28%
|
$27,272
$1.44 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-80.58%
|
$300,000
$12.3 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.62%
|
$0
$0.64 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
117,333
-46.25%
|
$1,407,996
$12.27 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,333
+31.62%
|
$0
$0.84 P/Share
|
|
Dec 11
2024
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,000
-71.35%
|
$180,000
$12.43 P/Share
|
|
Dec 11
2024
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+41.64%
|
$0
$0.64 P/Share
|
|
Dec 10
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-26.83%
|
$650,000
$13.15 P/Share
|
|
Dec 10
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.15%
|
$0
$0.84 P/Share
|
|
Dec 10
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-4.01%
|
$1,300,000
$13.17 P/Share
|
|
Dec 10
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-4.01%
|
$1,300,000
$13.17 P/Share
|
|
Dec 06
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Indirect |
11,876
+0.27%
|
$95,008
$8.42 P/Share
|
|
Dec 06
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,665
+0.37%
|
$102,660
$4.93 P/Share
|
|
Dec 06
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
25,665
+0.37%
|
$102,660
$4.93 P/Share
|
|
Dec 06
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,876
+0.27%
|
$95,008
$8.42 P/Share
|
|
Dec 06
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-26.83%
|
$700,000
$14.23 P/Share
|
|
Dec 06
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.15%
|
$0
$0.84 P/Share
|
|
Dec 05
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
49,640
-26.69%
|
$694,960
$14.13 P/Share
|
|
Dec 05
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,640
+21.06%
|
$0
$0.84 P/Share
|
|
Dec 04
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.95 P/Share
|
|
Dec 04
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.88%
|
$0
$0.84 P/Share
|
|
Dec 04
2024
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,283
-52.46%
|
$87,962
$14.0 P/Share
|
|
Dec 04
2024
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,283
+34.41%
|
$6,283
$1.5 P/Share
|
|
Dec 04
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
14,772
-6.56%
|
$192,036
$13.75 P/Share
|
|
Dec 04
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
14,772
+6.16%
|
$44,316
$3.15 P/Share
|
|
Dec 03
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.19 P/Share
|
|
Dec 03
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+10.49%
|
$0
$0.84 P/Share
|
|
Dec 03
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
87,984
-29.49%
|
$1,143,792
$13.26 P/Share
|
|
Dec 03
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
87,984
+13.54%
|
$175,968
$2.21 P/Share
|
|
Dec 02
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.67 P/Share
|
|
Dec 02
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.88%
|
$0
$0.84 P/Share
|
|
Dec 02
2024
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,717
-39.5%
|
$52,038
$14.11 P/Share
|
|
Dec 02
2024
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+28.32%
|
$3,717
$1.5 P/Share
|
|
Dec 02
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
97,244
-15.87%
|
$1,264,172
$13.95 P/Share
|
|
Dec 02
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
97,244
+14.18%
|
$97,244
$1.27 P/Share
|
|
Nov 27
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-15.49%
|
$350,000
$14.39 P/Share
|
|
Nov 26
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
42,186
-20.72%
|
$590,604
$14.05 P/Share
|
|
Nov 25
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
32,814
-13.88%
|
$459,396
$14.0 P/Share
|
|
Nov 19
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-3.79%
|
$1,300,000
$13.95 P/Share
|
|
Nov 19
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-3.79%
|
$1,300,000
$13.95 P/Share
|
|
Nov 12
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-1.9%
|
$1,700,000
$17.2 P/Share
|
|
Nov 12
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-1.9%
|
$1,700,000
$17.2 P/Share
|
|
Nov 12
2024
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,814
-0.17%
|
$591,838
$17.47 P/Share
|
|
Nov 11
2024
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
528,456
-2.4%
|
$8,983,752
$17.8 P/Share
|
|
Oct 16
2024
|
Kathleen D. Scott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-71.64%
|
$200,000
$16.0 P/Share
|
|
Oct 16
2024
|
Kathleen D. Scott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+41.74%
|
$12,500
$1.5 P/Share
|
|
Oct 15
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-2.39%
|
$1,400,000
$15.0 P/Share
|